Certara (CERT) Is Up 9.0% After Simcyp Simulator Wins EMA Qualification and Q2 Sales Rise—Has the Bull Case Changed?

• Earlier this month, Certara, Inc. reported its second quarter 2025 financial results, highlighted by a year-over-year sales increase to US$104.57 million and a narrowing net loss, and announced that the European Medicines Agency had formally qualified its Simcyp Simulator for regulatory submissions across the EU.
• This regulatory first for Certara’s Simcyp software enables more efficient drug submission processes and could accelerate biosimulation adoption among pharmaceutical companies operating in Europe.
• We’ll now examine how EMA qualification of the Simcyp Simulator shapes Certara’s investment narrative given the company’s recent operational progress.

Outshine the giants: these 18 early-stage AI stocks could fund your retirement.

Certara Investment Narrative Recap

Shareholders in Certara, Inc. are ultimately betting on the scaling of biosimulation in drug development and regulatory acceptance as a catalyst for adoption and revenue growth. The EMA qualification of Simcyp boosts the company's credibility with European regulators, enhancing short-term adoption potential, but the most significant risk remains any slowdown in large pharma customer spending or shifting industry budgets, which could offset near-term regulatory wins if macroeconomic uncertainty intensifies.

Among recent developments, Certara’s completed share buyback of 1,793,279 shares for US$23.43 million stands out but does not directly impact the regulatory and adoption catalysts created by the EMA Simcyp qualification, which are likely more material for revenue growth in the current context.

However, investors should also consider the ongoing risk that pharma sector caution and cost pressures could limit or delay software adoption despite new regulatory support, especially if...

Read the full narrative on Certara (it's free!)

Certara's projections forecast $520.7 million in revenue and $7.4 million in earnings by 2028. This scenario assumes an annual revenue growth rate of 8.7%, but earnings are expected to decrease by $0.6 million from the current $8.0 million.

Uncover how Certara's forecasts yield a $14.11 fair value, a 31% upside to its current price.

Exploring Other Perspectives

Fair value estimates from the Simply Wall St Community range from US$11.24 to US$14.11 across 2 perspectives. While the EMA’s Simcyp qualification points to a catalyst for growth, diverging views suggest investors weigh evolving adoption trends closely.

Explore 2 other fair value estimates on Certara - why the stock might be worth just $11.24!

Build Your Own Certara Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Certara research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Certara research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Certara's overall financial health at a glance.

Looking For Alternative Opportunities?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• We've found 19 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.
• Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com